Remicade (infliximab) is used to treat autoimmune diseases. It was initially approved by the U.S. Food and Drug Administration (FDA ) in August 1998 for the treatment of Crohn's disease. It has since additionally been approved by the FDA for the treatment of psoriasis, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, and rheumatoid arthritis.
Remicade is marketed by Centocor in the US. Centocor was purchased by Johnson & Johnson in 1998.
It was thought that infliximab, which is an artificial monoclonal antibody, works by preventing Tumor Necrosis Factor (TNF)-alpha from binding to its receptor in the cell. And this continues to explain its efficacy in treatment for rheumatoid arthritis. But infliximab's action in Crohn's disease is now assumed to be due to its resolution of activated T cells.
Regaedless of how it works, Remicade, along with other TNF blockers, came under the scrutiny of the FDA due, in part, to reports of lymphoma and other cancers in children and adolescents. The agency's analysis of such reports and of additional post-marketing reports and evaluations, prompted it to require the makers of such drugs to update the boxed warning in the prescribing information to alert healthcare professionals of an increased risk of lymphoma and other malignancies in children and adolescents treated with them.
It is also possible to get an allergic reaction or a serious, or even fatal, infection during treatment with Remicade. Medical help should be sought immediately if someone using Remicade experiences any of the following potential conditions, side effects or symptoms:
Allergies: hives; difficulty breathing; swelling of the face, lips, tongue, or throat
Infections: fever, chills, sweating, shortness of breath, tired feeling, cough, sore throat, weight loss, flu symptoms
Other side effects:
If you or a loved one has suffered or is suffering side effects associated with the use of Remicade or other TNF blockers, you may be entitled to compensation. Contact a qualified pharmaceutical injury attorney for an evaluation of your case.